

Michael W Lutz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1825337/publications.pdf>

Version: 2024-02-01

105
papers

2,894
citations

159585

30
h-index

189892

50
g-index

110
all docs

110
docs citations

110
times ranked

3493
citing authors

#	ARTICLE	IF	CITATIONS
1	The Cubic Ternary Complex Receptor-Occupancy Model III. Resurrecting Efficacy. <i>Journal of Theoretical Biology</i> , 1996, 181, 381-397.	1.7	190
2	Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgesics. <i>Journal of Medicinal Chemistry</i> , 1991, 34, 2202-2208.	6.4	188
3	The Cubic Ternary Complex Receptor Occupancy Model I. Model Description. <i>Journal of Theoretical Biology</i> , 1996, 178, 151-167.	1.7	176
4	Novel loci and pathways significantly associated with longevity. <i>Scientific Reports</i> , 2016, 6, 21243.	3.3	145
5	The effect of <i>TOMM40</i> polyA length on gray matter volume and cognition in middle-aged persons with <i>APOE</i> ϵ 3/ ϵ 3 genotype. <i>Alzheimer's and Dementia</i> , 2011, 7, 456-465.	0.8	103
6	The Cubic Ternary Complex Receptor Occupancy Model II. Understanding Apparent Affinity. <i>Journal of Theoretical Biology</i> , 1996, 178, 169-182.	1.7	97
7	Genetic variation at a single locus and age of onset for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2010, 6, 125-131.	0.8	90
8	The <i>cis</i> -regulatory effect of an Alzheimer's disease-associated polyA locus on expression of <i>TOMM40</i> and apolipoprotein E genes. <i>Alzheimer's and Dementia</i> , 2014, 10, 541-551.	0.8	73
9	Peak Alignment of Urine NMR Spectra Using Fuzzy Warping. <i>Journal of Chemical Information and Modeling</i> , 2006, 46, 863-875.	5.4	62
10	Longitudinal modeling of cognitive aging and the <i>TOMM40</i> effect. <i>Alzheimer's and Dementia</i> , 2012, 8, 490-495.	0.8	61
11	<i>TOMM40</i> and <i>APOE</i> : Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. <i>Alzheimer's and Dementia</i> , 2013, 9, 132-136.	0.8	59
12	Alzheimer's disease susceptibility genes <i>APOE</i> and <i>TOMM40</i> , and brain white matter integrity in the Lothian Birth Cohort 1936. <i>Neurobiology of Aging</i> , 2014, 35, 1513.e25-1513.e33.	3.1	58
13	Journal of Parkinson's disease & Alzheimer's disease. <i>Journal of Parkinson's Disease and Alzheimer's Disease</i> , 2014, 1, .	0.8	56
14	New applications of disease genetics and pharmacogenetics to drug development. <i>Current Opinion in Pharmacology</i> , 2014, 14, 81-89.	3.5	56
15	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 537-547.	10.2	55
16	The <i>Alu</i> neurodegeneration hypothesis: A primate-specific mechanism for neuronal transcription noise, mitochondrial dysfunction, and manifestation of neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 828-838.	0.8	51
17	A homopolymer polymorphism in the <i>TOMM40</i> gene contributes to cognitive performance in aging. <i>Alzheimer's and Dementia</i> , 2012, 8, 381-388.	0.8	49
18	Understanding the genetics of <i>APOE</i> and <i>TOMM40</i> and role of mitochondrial structure and function in clinical pharmacology of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 687-694.	0.8	49

#	ARTICLE	IF	CITATIONS
19	Experimental design for high-throughput screening. <i>Drug Discovery Today</i> , 1996, 1, 277-286.	6.4	48
20	Characterization of the Poly-T Variant in the TOMM40 Gene in Diverse Populations. <i>PLoS ONE</i> , 2012, 7, e30994.	2.5	47
21	<i>TOMM40</i> 523 variant and cognitive decline in older persons with <i>APOE</i> ϵ 3/ ϵ 3 genotype. <i>Neurology</i> , 2017, 88, 661-668.	1.1	45
22	Shared genetic etiology underlying Alzheimer's disease and major depressive disorder. <i>Translational Psychiatry</i> , 2020, 10, 88.	4.8	45
23	The effects of the <i>TOMM40</i> poly-T alleles on Alzheimer's disease phenotypes. <i>Alzheimer's and Dementia</i> , 2018, 14, 692-698.	0.8	41
24	On the importance of the "antagonist assumption" to how receptors express themselves. <i>Biochemical Pharmacology</i> , 1995, 50, 17-26.	4.4	40
25	Investigating Predictors of Cognitive Decline Using Machine Learning. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2020, 75, 733-742.	3.9	40
26	<i>APOE</i> ϵ 4- <i>TOMM40</i> 523 haplotypes and the risk of Alzheimer's disease in older Caucasian and African Americans. <i>PLoS ONE</i> , 2017, 12, e0180356.	2.5	39
27	Interactions of 1263W94 with Other Antiviral Agents in Inhibition of Human Cytomegalovirus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1468-1471.	3.2	38
28	Alzheimer's disease: diagnostics, prognostics and the road to prevention. <i>EPMA Journal</i> , 2010, 1, 293-303.	6.1	36
29	Assessment of the COBAS Amplicor HBV Monitor Test for Quantitation of Serum Hepatitis B Virus DNA Levels. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1972-1976.	3.9	33
30	Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA Research Framework. <i>Alzheimer's and Dementia</i> , 2018, 14, 532-534.	0.8	33
31	African-American <i>TOMM40</i> 523 <i>APOE</i> haplotypes are admixture of West African and Caucasian alleles. <i>Alzheimer's and Dementia</i> , 2014, 10, 592.	0.8	32
32	Alzheimer's Disease Susceptibility Genes <i>APOE</i> and <i>TOMM40</i> , and Hippocampal Volumes in the Lothian Birth Cohort 1936. <i>PLoS ONE</i> , 2013, 8, e80513.	2.5	29
33	The genetic contributions of <i>SNCA</i> and <i>LRRK2</i> genes to Lewy Body pathology in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 4814-4821.	2.9	28
34	New Genetic Approaches to AD: Lessons from <i>APOE</i> - <i>TOMM40</i> Phylogenetics. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 48.	4.2	28
35	A prognostic model of Alzheimer's disease relying on multiple longitudinal measures and time-to-event data. <i>Alzheimer's and Dementia</i> , 2018, 14, 644-651.	0.8	28
36	The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 661-670.	3.7	28

#	ARTICLE	IF	CITATIONS
37	A genetics-based biomarker risk algorithm for predicting risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 30-44.	3.7	26
38	Genetic analysis of Î±-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2017, 13, 1237-1250.	0.8	26
39	A systems-based model of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 168-171.	0.8	26
40	Bioinformatics strategy to advance the interpretation of Alzheimer's disease GWAS discoveries: The roads from association to causation. <i>Alzheimer's and Dementia</i> , 2019, 15, 1048-1058.	0.8	26
41	Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants. <i>Experimental Gerontology</i> , 2012, 47, 347-352.	2.8	25
42	The correlation of copy number variations with longevity in a genome-wide association study of Han Chinese. <i>Aging</i> , 2018, 10, 1206-1222.	3.1	25
43	The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes. <i>European Neuropsychopharmacology</i> , 2014, 24, 1492-1499.	0.7	24
44	Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 135-147.	3.3	23
45	A cytosine-thymine (CT)-rich haplotype in intron 4 of <i>SNCA</i> confers risk for Lewy body pathology in Alzheimer's disease and affects <i>SNCA</i> expression. <i>Alzheimer's and Dementia</i> , 2015, 11, 1133-1143.	0.8	22
46	Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults. <i>Journal of the Neurological Sciences</i> , 2016, 365, 89-95.	0.6	22
47	Leisure Activities, APOE Îµ4, and Cognitive Decline: A Longitudinal Cohort Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 736201.	3.4	20
48	Cerebrospinal fluid cortisol concentrations in healthy elderly are affected by both APOE and TOMM40 variants. <i>Psychoneuroendocrinology</i> , 2012, 37, 366-371.	2.7	17
49	The association between neighborhood socioeconomic status, cardiovascular and cerebrovascular risk factors, and cognitive decline in the Health and Retirement Study (HRS). <i>Aging and Mental Health</i> , 2020, 24, 1479-1486.	2.8	17
50	Interaction between APOE Îµ4 and dietary protein intake on cognitive decline: A longitudinal cohort study. <i>Clinical Nutrition</i> , 2021, 40, 2716-2725.	5.0	17
51	<i>APOE/TOMM40</i> Genetic Loci, White Matter Hyperintensities, and Cerebral Microbleeds. <i>International Journal of Stroke</i> , 2015, 10, 1297-1300.	5.9	15
52	The SSV Evaluation System: A Tool to Prioritize Short Structural Variants for Studies of Possible Regulatory and Causal Variants. <i>Human Mutation</i> , 2016, 37, 877-883.	2.5	15
53	Neighborhoods, sleep quality, and cognitive decline: Does where you live and how well you sleep matter?. <i>Alzheimer's and Dementia</i> , 2018, 14, 454-461.	0.8	15
54	Shared genetic etiology underlying late-onset Alzheimer's disease and posttraumatic stress syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, 1280-1292.	0.8	15

#	ARTICLE	IF	CITATIONS
55	Effect of APOE and CD33 on Cognitive Decline. PLoS ONE, 2015, 10, e0130419.	2.5	15
56	Interaction Between the <i>FOXO1A-209</i> Genotype and Tea Drinking Is Significantly Associated with Reduced Mortality at Advanced Ages. Rejuvenation Research, 2016, 19, 195-203.	1.8	14
57	Neuropathologic features of <i>TOMM40</i> '523 variant on late-life cognitive decline. Alzheimer's and Dementia, 2017, 13, 1380-1388.	0.8	14
58	Genetic and non-genetic factors associated with the phenotype of exceptional longevity & normal cognition. Scientific Reports, 2020, 10, 19140.	3.3	13
59	Family history and <i>TOMM40</i> '523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts. Alzheimer's and Dementia, 2017, 13, 1217-1225.	0.8	12
60	Characterization of <i>APOE</i> and <i>TOMM40</i> allele frequencies in the Japanese population. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 524-530.	3.7	12
61	Analysis of pleiotropic genetic effects on cognitive impairment, systemic inflammation, and plasma lipids in the Health and Retirement Study. Neurobiology of Aging, 2019, 80, 173-186.	3.1	12
62	APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid1. Journal of Alzheimer's Disease, 2021, 79, 511-530.	2.6	11
63	Translocase of Outer Mitochondrial Membrane 40 Homolog (TOMM40) Poly-T Length Modulates Lorazepam-Related Cognitive Toxicity in Healthy APOE ϵ 4-Negative Elderly. Journal of Clinical Psychopharmacology, 2011, 31, 544-546.	1.4	10
64	Towards precision medicine in Alzheimer's disease: deciphering genetic data to establish informative biomarkers. Expert Review of Precision Medicine and Drug Development, 2017, 2, 47-55.	0.7	9
65	Disease-modifying effects of an <i>SCAF4</i> structural variant in a predominantly <i>SOD1</i> ALS cohort. Neurology: Genetics, 2020, 6, e470.	1.9	9
66	Characteristics of strokes associated with centrifugal flow left ventricular assist devices. Scientific Reports, 2021, 11, 1645.	3.3	9
67	TOMM40&APOE haplotypes are associated with cognitive decline in non-demented Blacks. Alzheimer's and Dementia, 2021, 17, 1287-1296.	0.8	9
68	APOE, TOMM40, and sex interactions on neural network connectivity. Neurobiology of Aging, 2022, 109, 158-165.	3.1	8
69	Association Between Polygenic Risk Score and the Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1323-1335.	2.6	7
70	KRAX as parameter for classification. Trends in Pharmacological Sciences, 1988, 9, 351.	8.7	6
71	The Importance of Being Connected. Journal of Alzheimer's Disease, 2011, 24, 247-251.	2.6	6
72	New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia. Alzheimer's and Dementia, 2018, 14, 703-706.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Genetic Association Between Epigenetic Aging-Acceleration and the Progression of Mild Cognitive Impairment to Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 1734-1742.	3.6	6
74	A Triage Model for Interhospital Transfers of Low Risk Intracerebral Hemorrhage Patients. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105616.	1.6	5
75	How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 917-919.	0.8	5
76	Motor Evoked Potentials Double Train Stimulation: Optimal Number of Pulses per Train. <i>Journal of Clinical Neurophysiology</i> , 2022, 39, 401-405.	1.7	5
77	Bioinformatics pipeline to guide late-onset Alzheimer's disease (LOAD) post-GWAS studies: Prioritizing transcription regulatory variants within LOAD-associated regions. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12244.	3.7	5
78	A Bayesian perspective on Biogen's aducanumab trial. <i>Alzheimer's and Dementia</i> , 2022, 18, 2341-2351.	0.8	5
79	Managing genomic and proteomic knowledge. <i>Drug Discovery Today: Technologies</i> , 2005, 2, 197-204.	4.0	4
80	Likelihood ratio statistics for gene set enrichment in Alzheimer's disease pathways. <i>Alzheimer's and Dementia</i> , 2021, 17, 561-573.	0.8	4
81	Polygenic Risk Score Effectively Predicts Depression Onset in Alzheimer's Disease Based on Major Depressive Disorder Risk Variants. <i>Frontiers in Neuroscience</i> , 2022, 16, 827447.	2.8	4
82	P4-073: A PHARMACOGENETICS-SUPPORTED CLINICAL TRIAL TO DELAY ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE USING LOW-DOSE PIOGLITAZONE: AN UPDATE ON THE TOMORROW STUDY. <i>Alzheimer's and Dementia</i> , 2014, 10, P809.	0.8	3
83	Drug and tissue factors both confound KA measurements. <i>Trends in Pharmacological Sciences</i> , 1990, 11, 273-274.	8.7	2
84	Use of resampling techniques to estimate the variance of parameters in pharmacological assays when experimental protocols preclude independent replication: An example using schild regressions. <i>Journal of Pharmacological and Toxicological Methods</i> , 1995, 34, 37-46.	0.7	2
85	Socioeconomic Influence on Emergency Medical Services Utilization for Acute Stroke: Think Nationally, Act Locally. <i>Neurohospitalist, The</i> , 2021, 11, 317-325.	0.8	2
86	A mathematical model for analysis of pharmacologically induced changes in the kinetics of cardiac muscle. <i>Journal of Pharmacological and Toxicological Methods</i> , 1996, 36, 171-183.	0.7	0
87	P4-284: GENETIC RELATIONSHIP OF APOE AND TOMM40 HAPLOTYPES IN AFRICAN AMERICAN, WEST AFRICAN, AND CAUCASIAN COHORTS. , 2014, 10, P888-P888.		0
88	P3-021: IDENTIFICATION AND CHARACTERIZATION OF POLYMORPHIC STRUCTURAL VARIANTS ASSOCIATED WITH ALZHEIMER'S DISEASE AND DISEASES OF AGING. , 2014, 10, P635-P635.		0
89	P3-018: Tomm40/ApoE variation and age of onset of mild cognitive impairment and dementia in a prospective, longitudinal study. , 2015, 11, P626-P627.		0
90	P2-061: A multi-modal comparison of biomarkers stratified by a simple genetic risk prediction algorithm. , 2015, 11, P506-P506.		0

#	ARTICLE	IF	CITATIONS
91	P4-293: APOE-TOMM40 ϵ 23 Haplotypes and the Risk of Alzheimer's Disease in Older Caucasian and African Americans. , 2016, 12, P1146-P1146.		0
92	P4-295: <i>TOMM40</i> ϵ 23 Variant and Cognitive Decline in Community Based Older Persons with <i>APOE</i> E3/3 GENOTYPE. Alzheimer's and Dementia, 2016, 12, P1146.	0.8	0
93	[IC-066]: AD FAMILY HISTORY MODULATES EFFECTS OF TOMM40 ϵ 23 POLY ϵ ON MTL ATROPHY AND HYPOMETABOLISM IN PRECLINICAL AND AD COHORTS. Alzheimer's and Dementia, 2017, 13, P54.	0.8	0
94	[P-065]: THE DISTINCT CONTRIBUTION OF <i>SNCA</i> 3' UTR TO PARKINSON'S AND DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P629.	0.8	0
95	[P-082]: ANALYSIS OF PLEIOTROPIC GENETIC EFFECTS ON COGNITIVE IMPAIRMENT AND SYSTEMIC INFLAMMATION IN THE HEALTH AND RETIREMENT STUDY. Alzheimer's and Dementia, 2017, 13, P1290.	0.8	0
96	P3-070: ANALYSIS OF A SPORADIC MOUSE MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1091.	0.8	0
97	F2-03-01: UNTANGLING THE GENETIC COMPLEXITY OF LATE ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P604.	0.8	0
98	P2-616: LIGHT TO MODERATE ALCOHOL CONSUMPTION AND COGNITIVE DECLINE: FOCUS ON <i>APOE</i> ϵ 4 CARRIERS AND WOMEN IN THE HEALTH AND RETIREMENT STUDY. Alzheimer's and Dementia, 2018, 14, P977.	0.8	0
99	P3-116: ANALYSIS OF A SYSTEMIC INFLAMMATION-BASED POLYGENIC RISK SCORE ON EFFECTS ON COGNITIVE IMPAIRMENT IN THE HEALTH AND RETIREMENT STUDY. Alzheimer's and Dementia, 2018, 14, P1112.	0.8	0
100	P4-041: BIOINFORMATICS APPROACH FOR IDENTIFYING ACTIVE ENHANCERS THAT DRIVE ALZHEIMER'S DISEASE GENETIC ETIOLOGY. Alzheimer's and Dementia, 2018, 14, P1448.	0.8	0
101	Shared genetic etiology underlying late-onset Alzheimer's disease and post traumatic stress syndrome. Alzheimer's and Dementia, 2020, 16, e041284.	0.8	0
102	A genetic enrichment strategy for delay of onset of Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2020, 16, e044920.	0.8	0
103	Anticoagulation after Spontaneous Intraparenchymal Hemorrhage in Patients with Mechanical Heart Valves and Concomitant Atrial Fibrillation. Journal of Neuroanaesthesiology and Critical Care, 0, 08, .	0.2	0
104	Clinical Trials of AD Delay of Onset: Enrichment by a Prognostic Genetic Biomarker. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 141-160.	0.6	0
105	<i>APOE</i> , <i>TOMM40</i> , and Sex Interactions on Neural Network Connectivity. Alzheimer's and Dementia, 2021, 17, e058171.	0.8	0